Ken Griffin Design Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 100 shares of DSGN stock, worth $335. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 2,600
96.15%
Holding current value
$335
Previous $6,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding DSGN
# of Institutions
95Shares Held
30.5MCall Options Held
100Put Options Held
100-
Sr One Capital Management, LP6.53MShares$21.9 Million8.85% of portfolio
-
Logos Global Management LP San Francisco, CA5.03MShares$16.9 Million1.89% of portfolio
-
Black Rock Inc. New York, NY2.27MShares$7.62 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.66MShares$5.57 Million0.08% of portfolio
-
Tang Capital Management LLC San Diego, CA1.48MShares$4.96 Million0.73% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $187M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...